An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 358
- 主要终点
- Change From Baseline in Intraocular Pressure (IOP) in the Left Eye
研究概览
简要总结
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). The decision to change medications lies with the physician according to their standard practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT)
- •Previously prescribed any IOP-lowering therapy which has been stopped and a new prostaglandin analogue -containing IOP-lowering therapy started
排除标准
- 未提供
研究组 & 干预措施
Patients with POAG or OHT
Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
干预措施: Prostaglandin Analogue -Containing IOP-Lowering Therapy (Drug)
结局指标
主要结局
Change From Baseline in Intraocular Pressure (IOP) in the Left Eye
时间窗: Baseline, Week 12
IOP is a measurement of the fluid pressure inside the eye. A negative change from Baseline indicates an improvement.
Change From Baseline in Intraocular Pressure (IOP) in the Right Eye
时间窗: Baseline, Week 12
IOP is a measurement of the fluid pressure inside the eye. A negative change from Baseline indicates an improvement.
次要结局
- Patient Assessment of Overall Tolerability With New Treatment Using a 4-Point Scale(12 Weeks)
- Physician Assessment of Tolerability With New Treatment Using a 4-Point Scale(12 Weeks)
- Percentage of Participants Who Discontinue the Use of New Treatment Prior to 12 Weeks(12 Weeks)
- Percentage of Participants Who Continue the New Treatment After 12 Weeks(12 Weeks)
- Physician Assessment of Adherence to New Treatment Using a 4-Point Scale(12 Weeks)
- Percentage of Participants Reaching Individual IOP Target After 12 Weeks(12 Weeks)
- Physician Assessment of Efficacy Using a 5-Point Scale(12 Weeks)